Scarica l'app Stockscreener
33.16
3.62%
-1.245
Dopo l'orario di chiusura:
33.16
Precedente Chiudi:
$34.41
Aprire:
$34.55
Volume 24 ore:
58,208
Relative Volume:
1.01
Capitalizzazione di mercato:
$130.61M
Reddito:
$17,000
Utile/perdita netta:
$-31.08M
Rapporto P/E:
-9.9095
EPS:
-3.3463
Flusso di cassa netto:
$-24.86M
1 W Prestazione:
-9.13%
1M Prestazione:
+1.22%
6M Prestazione:
+22.81%
1 anno Prestazione:
+86.71%
Intervallo 1D:
$33.15
$37.40
Intervallo di 1 settimana:
$33.15
$37.41
Portata 52W:
$14.00
$44.00
Vtv Therapeutics Inc Stock (VTVT) Company Profile
Nome
Vtv Therapeutics Inc
Settore
Industria
Telefono
336-841-0300
Indirizzo
3980 PREMIER DR, HIGH POINT, NC
Compare VTVT vs VRTX, REGN, ARGX, ALNY, RVMD
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
VTVT
Vtv Therapeutics Inc
|
33.16 | 135.51M | 17,000 | -31.08M | -24.86M | -3.3463 |
VRTX
Vertex Pharmaceuticals Inc
|
435.93 | 110.28B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
634.62 | 66.98B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
808.43 | 50.15B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
295.50 | 39.71B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
154.89 | 32.22B | 742.00K | -1.37B | -1.07B | -7.0731 |
Vtv Therapeutics Inc Stock (VTVT) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-03-12 | Iniziato | Evercore ISI | Outperform |
| 2026-01-23 | Iniziato | Roth Capital | Buy |
| 2026-01-05 | Iniziato | TD Cowen | Buy |
| 2025-11-19 | Iniziato | BTIG Research | Buy |
| 2019-05-30 | Iniziato | H.C. Wainwright | Buy |
| 2018-04-10 | Downgrade | Stifel | Buy → Hold |
| 2018-03-08 | Iniziato | ROTH Capital | Buy |
| 2018-02-08 | Iniziato | Northland Capital | Outperform |
| 2016-09-26 | Iniziato | H.C. Wainwright | Buy |
| 2015-09-04 | Iniziato | Canaccord Genuity | Buy |
| 2015-08-24 | Iniziato | Piper Jaffray | Overweight |
| 2015-08-24 | Iniziato | Stifel | Buy |
Mostra tutto
Vtv Therapeutics Inc Borsa (VTVT) Ultime notizie
vTv Therapeutics Inc. Q1 2026 Earnings: Massive EPS Surprise Amid Revenue Shortfall and Stock DeclineSenior Analyst Forecasts - Newser
vTv Therapeutics Inc. (VTVT) Q1 2026 Earnings: Massive EPS Surprise Despite No RevenueAnalyst Stock Picks - Newser
VTVT | vTv Therapeutics Inc. Class Insider Trading - Quiver Quantitative
VTVT Technical Analysis | Trend, Signals & Chart Patterns | VTV THERAPEUTICS INC- CL A (NASDAQ:VTVT) - ChartMill
vTv Therapeutics Inc. (NASDAQ:VTVT) Just Beat Earnings: Here's What Analysts Think Will Happen Next - Yahoo Finance
(VTVT) as a Liquidity Pulse for Institutional Tactics - Stock Traders Daily
vTv Therapeutics (VTVT) Q1 2026 Earnings: EPS $1.65 Beats EstimatesRevenue Report - newser.com
vTv Therapeutics (VTVT) is on the Move, Here's Why the Trend Could be Sustainable - Yahoo Finance
TD Cowen Maintains VTv Therapeutics(VTVT.US) With Buy Rating, Maintains Target Price $67 - Moomoo
Analyst Maintains Buy on vTv Therapeutics, Reiterates Unchanged $49 Price Target Amid Progress of Cadisegliatin Program - TipRanks
H.C. Wainwright cuts vTv Therapeutics stock price target to $45 By Investing.com - Investing.com Nigeria
H.C. Wainwright cuts vTv Therapeutics stock price target to $45 - Investing.com
vTv Therapeutics Inc. Files Form 8-K for Class A Common Stock on Nasdaq – Company Information and SEC Filing Details - Minichart
vTv Therapeutics (VTVT) Reports Strong Q1 Revenue and Trial Prog - GuruFocus
Is vTv Therapeutics (VTVT) 322.2% Overvalued After Q1 2026? EPS - GuruFocus
vTv Therapeutics Expands At-The-Market Share Program Capacity - TipRanks
Recent filings by vTv Therapeutics Inc. to the U.S. Securities and Exchange Commission (SEC) show that the company has increased its allocation of Class A common shares issued under the at-the-market offering (ATM) plan to the full amount. - Bitget
vTv Therapeutics (NASDAQ: VTVT) registers $47.5M ATM to fund cadisegliatin - Stock Titan
vTv Therapeutics (VTVT) expands ATM share offering, files Dechert legal opinion - Stock Titan
vTv Therapeutics Inc reports results for the quarter ended March 31Earnings Summary - TradingView
vTv Therapeutics Inc. 1Q 2026: Revenue $36.8M, Net income $24.1M — 10-Q Summary - TradingView
Licensing windfall lifts vTv Therapeutics (NASDAQ: VTVT) to Q1 2026 profit and stronger cash - Stock Titan
[8-K] vTv Therapeutics Inc. Reports Material Event - Stock Titan
vTv Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update - The Manila Times
VTv Therapeutics: Q1 Earnings Snapshot - kare11.com
Oral type 1 diabetes drug advances: vTv expects cash through Phase 3 data - Stock Titan
VTv Therapeutics Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com
MSN Money - MSN
TradingKey - TradingKey
vTv Therapeutics (VTVT) Projected to Post Earnings on Wednesday - MarketBeat
vTv Therapeutics Inc. (NASDAQ:VTVT) Given Average Rating of "Moderate Buy" by Analysts - MarketBeat
vTv Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Two new vTv hires get 39,500 stock options at $32 a share - Stock Titan
What vTv Therapeutics (VTVT) is doing to expand margins | Q4 2025: Profit Exceeds ViewsCertified Trade Ideas - Newser
vTv Therapeutics to Participate in Upcoming May Investor Conferences - The Manila Times
vTv Therapeutics lines up two May investor fireside chats - Stock Titan
VTv Therapeutics to Participate in Upcoming May Investor Conferences - marketscreener.com
vTv Therapeutics (NASDAQ:VTVT) Stock Price Passes Below Fifty Day Moving AverageWhat's Next? - MarketBeat
(VTVT) Risk Channels and Responsive Allocation - Stock Traders Daily
Vtv Therapeutics Inc Azioni (VTVT) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.98%
0.12%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):